New trials, publications, preprints and grants on this target, month by month.
Trial
Study of ACC-1898 in Adult Participants With Advanced Solid Tumors
1 Jan 2027· PHASE1 · NOT_YET_RECRUITING· CTGOV
Publication
β-elemene suppressed EMT via IGF1R inhibition in osimertinib treated AXL low-expressing EGFR mutant non-small cell lung cancer.
2 Nov 2026· European journal of pharmacology· PUBMED
Publication
GPR183 senses 7α,25-OHC to drive Treg differentiation and tumor immune evasion via AXL-JAK2-STAT5 signaling.
30 Oct 2026· Science advances· PUBMED
Publication
AXL-directed antibody-drug conjugate therapy in soft-tissue sarcoma.
16 Oct 2026· Journal of hematology & oncology· PUBMED
Publication
Inhibition of the MEK-ERK signaling pathway reverses acquired osimertinib resistance in NSCLC attributed to AXL overexpression.
13 Oct 2026· Life sciences· PUBMED
Publication
AXL and enolase 2 associate with therapy resistance to tyrosine kinase inhibitors lenvatinib and cabozantinib in renal cancer cells.
13 Oct 2026· Journal of proteomics· PUBMED
Publication
Intercellular GAS6-AXL signaling triggers podocyte cuproptosis in acute kidney injury upstream regulated by CEBPD.
9 Oct 2026· PloS one· PUBMED
Publication
Targeting the EpCAM-AXL axis to overcome drug resistance in lung cancer.
6 Oct 2026· Molecular oncology· PUBMED
Publication
AXL at the nexus of therapeutic resistance, tumor vascularization, and immune evasion in cancer.
25 Sept 2026· iScience· PUBMED
Publication
Mechanistic insights into VSIR-mediated AXL regulation and gastric cancer proliferation.
18 Sept 2026· iScience· PUBMED
Publication
AXL drives immunotherapy resistance by modulating IL-17 in bladder cancer.
18 Sept 2026· Biochemical pharmacology· PUBMED
Preprint
ZNF217 promotes receptor tyrosine kinase plasticity and AXL-ERK dependency in ovarian cancer.
14 Sept 2026· bioRxiv : the preprint server for biology· PUBMED
Publication
SERINC2-mediated phosphatidylserine remodeling activates protrusion-localized AXL signaling to promote brain metastasis.
10 Sept 2026· Cell reports· PUBMED
Publication
The SPA17-AXL axis drives melanoma aggressiveness and SPA17-targeting vaccination exhibits antitumor efficacy.
9 Sept 2026· Frontiers in immunology· PUBMED
Publication
Targeting Compensatory AKT Activation Overcomes Resistance to AXL Inhibition in Acute Lymphoblastic Leukemia.
5 Sept 2026· Molecular cancer therapeutics· PUBMED
Publication
Correction: Inhibition of AXL enhances chemosensitivity of human ovarian cancer cells to cisplatin via decreasing glycolysis.
1 Sept 2026· Acta pharmacologica Sinica· PUBMED
Publication
TP53 mutation promotes sunitinib resistance in gallbladder cancer via the ARHGEF7-AS2/miR-326/AXL pathway.
25 Aug 2026· Acta pharmaceutica Sinica. B· PUBMED
Publication
Correction: Song et al. AXL Inactivation Inhibits Mesothelioma Growth and Migration via Regulation of p53 Expression. Cancers 2020, 12, 2757.
18 Aug 2026· Cancers· PUBMED
Publication
1D228 Attenuates Sorafenib Resistance in Renal Cell Carcinoma Models by Dual Targeting c-Met and AXL.
12 Aug 2026· Cells· PUBMED
Preprint
Concurrent AXL Inhibition Enhances RAS and ERK Inhibitor Efficacy in KRAS -mutant Pancreatic and Lung Cancer.
11 Aug 2026· bioRxiv : the preprint server for biology· PUBMED
Publication
AXL phosphosite mapping links FAK1 and YAP1 signaling to erlotinib resistance in EGFR-mutant lung cancer.
20 Jul 2026· Cell reports· PUBMED
Publication
RETRACTED: Yen et al. n-Butylidenephthalide Regulated Tumor Stem Cell Genes EZH2/AXL and Reduced Its Migration and Invasion in Glioblastoma. Int. J. Mol. Sci. 2017, 18, 372.
8 Jul 2026· International journal of molecular sciences· PUBMED
Publication
[Gilteritinib enhances the inhibitory effect of dabrafenib on anaplastic thyroid carcinoma cells by suppressing the AXL signaling pathway].
6 Jul 2026· Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences· PUBMED
Publication
Inhibition of AXL receptor tyrosine kinase increases osteoblast function and bone mass.
6 Jul 2026· Bone research· PUBMED
Publication
RETRACTED: Zito Marino et al. AXL and MET Tyrosine Kinase Receptors Co-Expression as a Potential Therapeutic Target in Malignant Pleural Mesothelioma. J. Pers. Med. 2022, 12, 1993.
30 Jun 2026· Journal of personalized medicine· PUBMED
Publication
Receptor-Ligand Biomarker Profile in Ankylosing Spondylitis: Associations Between AXL/MERTK Expression, Circulating GAS6 and Protein S Levels, and Disease Activity.
26 Jun 2026· Life (Basel, Switzerland)· PUBMED
Publication
Discovery of potential AXL inhibitors using virtual screening, molecular docking, molecular dynamics, molecular mechanics, and in vitro validation.
23 Jun 2026· Scientific reports· PUBMED
Publication
C3+ cancer-associated fibroblast-derived GAS6 promotes cervical cancer metastasis via activation of AXL signaling pathway in a syngeneic orthotopic mouse model.
8 Jun 2026· Journal of translational medicine· PUBMED
Publication
AXL-mRNA Overexpression in Size-Based Enriched Circulating Tumor Cells as a Potential Biomarker for Anti-AXL Targeted Therapies in Non-Small-Cell Lung Cancer.
28 May 2026· Cancers· PUBMED
Publication
Association of Serum AXL and Gas6 Levels with Clinical Outcomes in Non-Hodgkin Lymphoma Patients with Post-Chemotherapy Infection.
25 May 2026· Infection and drug resistance· PUBMED